Trial Profile

GALADON - Molecular Imaging Response Assessment of Bevacizumab+Docetaxel as Neoadjuvant Chemotherapy in Primary Breast Cancer

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Docetaxel (Primary) ; Trastuzumab
Indications Breast cancer
Focus Therapeutic Use
Acronyms GALADON

Most Recent Events

09 Aug 2018 Status changed from recruiting to discontinued.
05 Dec 2015 Status changed from recruiting to discontinued as reported by European Clinical Trials Database
18 Jun 2015 Planned End Date changed from 1 Sep 2019 to 1 Sep 2022, according to to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com